Beximco Pharmaceuticals Ltd Payment of Cash Dividend (8937C)
July 01 2016 - 1:00AM
UK Regulatory
TIDMBXP
RNS Number : 8937C
Beximco Pharmaceuticals Ltd
01 July 2016
BEXIMCO PHARMACEUTICALS LTD.
01 July, 2016
Payment of Cash Dividend
Beximco Pharmaceuticals Limited ("BPL", "Beximco Pharma" or
"Company"; AIM Symbol: BXP), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical
ingredients, today announces that the cash dividend of 10% of the
nominal value per ordinary share/GDR (Taka 1 per ordinary
share/GDR) for the year 2015, which was decided in the Board
meeting held on 20(th) April, 2016, has been deposited with the
custodian bank in Dhaka for onward credit to respective GDR
holders' accounts.
For any queries regarding the credit of dividend to respective
accounts of holders of GDRs, please contact the Depository (Bank of
New York Mellon) representative, Mr. Vinu Kurian, at
vinu.kurian@bnymellon.com.
For further information please visit www.beximcopharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
Md. Asad Ullah, FCS, Executive Director & Company
Secretary
Tel; +880 2 58611891, +880 2 58612040, Ext 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Sean Wyndham-Quin
Tel: +44 (0)20 3368 3551 / 3555
Daniel Stewart & Company plc (Broker)
Martin Lampshire
Tel: +44 (0)20 7776 6550
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma
manufactures and sells generic pharmaceutical formulation products
and active pharmaceutical ingredients. The Company also undertakes
contract manufacturing for multinational and leading global generic
pharmaceutical companies. The Company operates from a 23 acre site
in Dhaka and has manufacturing facilities for producing various
drugs in different delivery systems such as tablets, capsules,
liquids, semi-solids, intravenous fluids, metered dose inhalers,
dry powder inhalers, sterile ophthalmic drops, prefilled syringes,
injectables, nebulizer solutions, oral soluble films etc. Ensuring
access to quality medicines is the powerful aspiration that
motivates 3,000 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Australia,
Europe, Latin America and Canada among others. The Company's
products are sold to retail outlets, medical institutions and other
pharmaceutical manufacturers in Bangladesh, in regional markets
such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and
in other markets overseas, principally in Africa, including South
Africa, Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria;
Pacific Island; Latin and Central American countries; Middle East;
Central Asia including Azerbaijan; South East Asia, including
Singapore, Taiwan, Malaysia, Indonesia, Philippines and Hong Kong;
Europe, including Austria, Germany and Romania and Australia.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DIVAKKDPABKDOAN
(END) Dow Jones Newswires
July 01, 2016 02:00 ET (06:00 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Apr 2024 to May 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From May 2023 to May 2024